Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vildagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 17/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vildagliptin SCHEMBL29369942 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL27193113 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL10031674 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16153676 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16155482 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16579 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16823370 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665400 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL671629 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL354910 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045509-A1 | MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS | LOEFFLER BERND MICHAEL (CH) | 2012-02-23 | — | — | US | claimed |
| EP-1917001-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | claimed |
| US-20070098781-A1 | Modified release compositions for DPP-IV inhibitors | HOFFMANN-LA ROCHE INC. | 2007-05-03 | — | — | US | claimed |
| WO-2007017423-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | claimed |
| US-9522175-B2 | Method of enhancing diabetes resolution | HAMILTON SCIENTIFIC, LTD. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140243263-A1 | METHOD OF ENHANCING DIABETES RESOLUTION | HAMILTON SCIENTIFIC, LTD. | 2014-08-28 | — | — | US | disclosed |
| US-8710002-B2 | Methods of enhancing diabetes resolution | HAMILTON SCIENTIFIC, LTD. | 2014-04-29 | — | — | US | disclosed |
| EP-2224945-B1 | METHODS OF ENHANCING DIABETES RESOLUTION | ROTHKOPF MICHAEL (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120045509-A1 | MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS | LOEFFLER BERND MICHAEL (CH) | 2012-02-23 | — | — | US | disclosed |
| US-20100317576-A1 | METHODS OF ENHANCING DIABETES RESOLUTION | HAMILTON SCIENTIFIC, LTD. | 2010-12-16 | — | — | US | disclosed |
| EP-1917001-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20070098781-A1 | Modified release compositions for DPP-IV inhibitors | HOFFMANN-LA ROCHE INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007017423-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070098781-A1 | Modified release compositions for DPP-IV inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 62/4885DPP8 5/4885 |
| US-20120045509-A1 | MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 62/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.